Tenaya’s cardiomyopathy gene therapy gets fast track boost
Pharmaceutical Technology
MAY 3, 2023
The US Food and Drug Administration (FDA) has granted Tenaya Therapeutics’ gene therapy TN-201 a fast track designation for the treatment of myosin binding protein C3 (MYBPC3)-associated hypertrophic cardiomyopathy (HCM). In January 2023, Tenaya announced FDA clearance for its Investigational New Drug (IND) application for TN-201.
Let's personalize your content